BIOMAT Database Logo BIOMAT Database Logo

[One year outcomes of pars plana vitrectomy in proliferative diabetic retinopathy]. 2014

Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji

OBJECTIVE To evaluate the 1-year results of pars plana vitrectomy for proliferative diabetic retinopathy. METHODS Two hundred thirty six patients with proliferative diabetic retinopathy received primary vitreous surgery at Shiga University of Medical Science Hospital and had at least 1 year follow-up period. The indications for pars plana vitrectomy included vitreous hemorrhage in 140 eyes, extramacular tractional retinal detachment in 60 eyes, macular tractional retinal detachment in 24 eyes and combined tractional retinal detachment in 12 eyes. The visual acuity and changes in visual acuity at 1-year postoperatively were evaluated. Preoperative bevacizumab injection and postoperative visual outcomes were compared between patients treated with 20 gauge (20 G) surgery and with micro incision vitrectomy surgery (MIVS). RESULTS The visual acuity improved by 3 lines or more in 166 eyes (70%) and remained unchanged in 56 eyes (24%); it decreased by 3 lines or more in 14 eyes (6%). Tractional retinal detachment in MIVS received more bevacizumab injections. MIVS systems achieved better visual results in the combined tractional retinal detachment group than 20 G system. CONCLUSIONS Successful visual improvement at 1-year postoperatively was observed in eyes with proliferative diabetic retinopathy after pars plana vitrectomy. Results of this study may suggest the superior performance of MIVS for pars plana vitrectomy in proliferative diabetic retinopathy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003930 Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION. Diabetic Retinopathies,Retinopathies, Diabetic,Retinopathy, Diabetic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068258 Bevacizumab An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS. Avastin,Bevacizumab-awwb,Mvasi,Bevacizumab awwb
D014792 Visual Acuity Clarity or sharpness of OCULAR VISION or the ability of the eye to see fine details. Visual acuity depends on the functions of RETINA, neuronal transmission, and the interpretative ability of the brain. Normal visual acuity is expressed as 20/20 indicating that one can see at 20 feet what should normally be seen at that distance. Visual acuity can also be influenced by brightness, color, and contrast. Acuities, Visual,Acuity, Visual,Visual Acuities
D014821 Vitrectomy Removal of the whole or part of the vitreous body in treating endophthalmitis, diabetic retinopathy, retinal detachment, intraocular foreign bodies, and some types of glaucoma. Vitrectomies
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji
[Pars plana vitrectomy in proliferative diabetic retinopathy].
April 1986, Klinische Monatsblatter fur Augenheilkunde,
Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji
Pars plana vitrectomy. Vitrectomy in diabetic retinopathy.
January 1976, Transactions. Section on Ophthalmology. American Academy of Ophthalmology and Otolaryngology,
Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji
Pars Plana Vitrectomy Reoperations for Complications of Proliferative Diabetic Retinopathy.
January 2020, Clinical ophthalmology (Auckland, N.Z.),
Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji
[Four-port pars plana vitrectomy for severe proliferative diabetic retinopathy].
January 2008, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology,
Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji
[Visual course for proliferative diabetic retinopathy after pars plana vitrectomy].
May 2007, Nippon Ganka Gakkai zasshi,
Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji
[Epiretinal membrane formation after pars plana vitrectomy in proliferative diabetic retinopathy].
April 1992, Klinische Monatsblatter fur Augenheilkunde,
Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji
Pars plana vitrectomy and silicone oil injection in proliferative diabetic retinopathy.
January 1989, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji
Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.
June 2024, JAMA ophthalmology,
Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji
Outcomes of 25-gauge pars plana vitrectomy in the surgical management of proliferative diabetic retinopathy.
January 2011, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye,
Masaki Tadera, and Hajime Kawamura, and Masato Fujikawa, and Masashi Kakinoki, and Tomoko Sawada, and Yoshitsugu Saishin, and Masahito Ohji
Clinical Characteristics and Surgical Outcomes of Patients Undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
March 2024, Ophthalmology. Retina,
Copied contents to your clipboard!